Krysov Sergey V, Rowley Tania F, Al-Shamkhani Aymen
Tenovus Research Laboratory, Southampton General Hospital, Tremona Road, Southampton SO16 6YD, United Kingdom.
Mol Cancer Ther. 2007 Feb;6(2):703-11. doi: 10.1158/1535-7163.MCT-06-0544.
CD30, a non-death domain-containing member of the tumor necrosis factor receptor superfamily, triggers apoptosis in anaplastic large cell lymphoma cells. The CD30 signaling pathways that lead to the induction of apoptosis are poorly defined. Here, we show that the induction of apoptosis by CD30 requires concurrent inhibition of p38 mitogen-activated protein kinase, which itself is activated by engagement of CD30 with CD30 ligand. Treatment of anaplastic large cell lymphoma cells with CD30 ligand and pharmacologic inhibitors of p38 mitogen-activated protein kinase, but not with CD30 ligand or inhibitors alone, triggered the activation of caspase-8 and the induction of apoptosis. Caspase-8 activation occurred within a few hours (2.5-4 h) after receptor triggering, was unaffected by the neutralization of ligands for the death domain-containing receptors TNFR1, Fas, DR3, DR4, or DR5, but was abolished by the expression of a dominant-negative form of the adaptor protein FADD. Importantly, we show that expression of the caspase-8 inhibitor c-FLIP(S) is strongly induced by the CD30 ligand, and that this is dependent on the activation of p38 mitogen-activated protein kinase. Thus, we provide evidence that the induction of apoptosis by CD30 in anaplastic large cell lymphoma cells is normally circumvented by the activation of p38 mitogen-activated protein kinase. These findings have implications for CD30-targeted immunotherapy of anaplastic large cell lymphoma.
CD30是肿瘤坏死因子受体超家族中不含死亡结构域的成员,可诱导间变性大细胞淋巴瘤细胞凋亡。导致凋亡诱导的CD30信号通路目前尚不清楚。在此,我们表明CD30诱导凋亡需要同时抑制p38丝裂原活化蛋白激酶,而p38丝裂原活化蛋白激酶本身是由CD30与CD30配体结合激活的。用CD30配体和p38丝裂原活化蛋白激酶的药理学抑制剂处理间变性大细胞淋巴瘤细胞,而不是单独使用CD30配体或抑制剂,可触发半胱天冬酶-8的激活和凋亡的诱导。半胱天冬酶-8的激活在受体触发后数小时内(2.5-4小时)发生,不受含死亡结构域受体TNFR1、Fas、DR3、DR4或DR5配体中和的影响,但被接头蛋白FADD的显性负性形式的表达所消除。重要的是,我们表明半胱天冬酶-8抑制剂c-FLIP(S)的表达被CD30配体强烈诱导,并且这依赖于p38丝裂原活化蛋白激酶的激活。因此,我们提供的证据表明,在间变性大细胞淋巴瘤细胞中,CD30诱导的凋亡通常被p38丝裂原活化蛋白激酶的激活所规避。这些发现对间变性大细胞淋巴瘤的CD30靶向免疫治疗具有重要意义。